Zai Lab Limited (ZLAB)
NASDAQ: ZLAB · Real-Time Price · USD
21.60
-1.55 (-6.70%)
Nov 7, 2025, 12:10 PM EST - Market open
Zai Lab Employees
Zai Lab had 1,869 employees as of December 31, 2024. The number of employees decreased by 306 or -14.07% compared to the previous year.
Employees
1,869
Change (1Y)
-306
Growth (1Y)
-14.07%
Revenue / Employee
$236,292
Profits / Employee
-$110,654
Market Cap
2.40B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1,869 | -306 | -14.07% |
| Dec 31, 2023 | 2,175 | 139 | 6.83% |
| Dec 31, 2022 | 2,036 | 85 | 4.36% |
| Dec 31, 2021 | 1,951 | 757 | 63.40% |
| Dec 31, 2020 | 1,194 | 502 | 72.54% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ZLAB News
- 4 hours ago - Zai Lab Limited (ZLAB) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 1 day ago - Zai Lab Announces Third Quarter 2025 Financial Results and Recent Corporate Updates - Business Wire
- 7 days ago - Zai Lab Announces Participation in Investor Conferences in November and December 2025 - Business Wire
- 13 days ago - Zai Lab Limited (ZLAB) Discusses Updated Monotherapy Phase I Data for Suzhou and Outlines Next Steps in Clinical Development Transcript - Seeking Alpha
- 14 days ago - Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for Small Cell Lung Cancer, and Initiation of Global Phase 3 Registrational Study - Business Wire
- 23 days ago - Zai Lab to Announce Third Quarter 2025 Financial Results and Recent Corporate Updates on November 6, 2025 - Business Wire
- 25 days ago - Zai Lab Announces Oral Presentation of Updated Data from Global Phase 1 Trial of Zocilurtatug Pelitecan (ZL-1310), a Potential First-in-Class DLL3-Targeted ADC, at 2025 AACR-NCI-EORTC Conference - Business Wire
- 2 months ago - Zai Lab's Double Whammy: Earnings Miss, Phase 3 Setback - Benzinga